Daniel Eiger
About
Daniel Eiger is a scholar working on Oncology, Cancer Research and Pulmonary and Respiratory Medicine.
According to data from OpenAlex, Daniel Eiger has authored 34 papers receiving a total of 595 indexed citations (citations by other indexed papers that have themselves been cited), including 29 papers in Oncology, 11 papers in Cancer Research and 10 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Daniel Eiger's work include HER2/EGFR in Cancer Research (18 papers), Breast Cancer Treatment Studies (10 papers) and Advanced Breast Cancer Therapies (9 papers). Daniel Eiger is often cited by papers focused on HER2/EGFR in Cancer Research (18 papers), Breast Cancer Treatment Studies (10 papers) and Advanced Breast Cancer Therapies (9 papers). Daniel Eiger collaborates with scholars based in Belgium, Brazil and Switzerland. Daniel Eiger's co-authors include Evandro de Azambuja, Elisa Agostinetto, Mariana Brandão, Rafael Caparica, Martine Piccart, Noam Pondé, Ahmad Awada, Eleonora Restuccia, Kevin Punie and Maria Alice Franzoi and has published in prestigious journals such as Journal of Clinical Oncology, JNCI Journal of the National Cancer Institute and Cancer Research.
In The Last Decade
Daniel Eiger
31 papers receiving 590 citations
Peers
Daniel Eiger
James Hu United States
Birgitta I. Hiddinga Netherlands
Georgios Tsakonas Sweden
J. Crawford United States
Hirak Der‐Torossian United States
İbrahim Petekkaya Türkiye
Munveer S. Bhangoo United States
Hiroshi Hongo Japan
Eirini Papadopoulou Greece
Alexandre de Nonneville France
Citations per year, relative to Daniel Eiger Daniel Eiger (= 1×)
peers
James Hu
Countries citing papers authored by Daniel Eiger
Since
Specialization
Citations
This map shows the geographic impact of Daniel Eiger's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Daniel Eiger with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Daniel Eiger more than expected).
Fields of papers citing papers by Daniel Eiger
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Daniel Eiger. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Daniel Eiger. The network helps show where Daniel Eiger may publish in the future.
Co-authorship network of co-authors of Daniel Eiger
This figure shows the co-authorship network connecting the top 25 collaborators of Daniel Eiger. A scholar is included among the top collaborators of Daniel Eiger based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Daniel Eiger. Daniel Eiger is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Harper‐Wynne, Catherine, Yeon Hee Park, Fábio Franke, et al.. (2024). heredERA Breast Cancer: a phase III, randomized, open-label study evaluating the efficacy and safety of giredestrant plus the fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection in patients with previously untreated HER2-positive, estrogen receptor-positive locally advanced or metastatic breast cancer. BMC Cancer. 24(1). 641–641.
2.
Küemmel, Sherko, Catherine Harper‐Wynne, Fábio Franke, et al.. (2023). Abstract OT2-03-01: heredERA Breast Cancer: Phase III study of first-line, fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection ± giredestrant (GDC-9545) for estrogen receptor+, HER2+ advanced breast cancer. Cancer Research. 83(5_Supplement). OT2–3.
3.
Martins-Branco, Diogo, Marie Kassapian, Véronique Debien, et al.. (2023). The impact of erythropoiesis-stimulating agents administration concomitantly with adjuvant anti-HER2 treatments on the outcomes of patients with early breast cancer: a sub-analysis of the ALTTO study. Breast Cancer Research and Treatment. 203(3). 497–509.
4.
Huober, Jens, Carlos H. Barrios, Naoki Niikura, et al.. (2022). Atezolizumab With Neoadjuvant Anti–Human Epidermal Growth Factor Receptor 2 Therapy and Chemotherapy in Human Epidermal Growth Factor Receptor 2–Positive Early Breast Cancer: Primary Results of the Randomized Phase III IMpassion050 Trial. Journal of Clinical Oncology. 40(25). 2946–2956.
5.
Dang, Chau T., Michael S. Ewer, Suzette Delaloge, et al.. (2022). BERENICE Final Analysis: Cardiac Safety Study of Neoadjuvant Pertuzumab, Trastuzumab, and Chemotherapy Followed by Adjuvant Pertuzumab and Trastuzumab in HER2-Positive Early Breast Cancer. Cancers. 14(11). 2596–2596.
6.
Marta, Guilherme Nader, Véronique Debien, Daniel Eiger, et al.. (2022). Outcomes of patients with small and node-negative HER2-positive early breast cancer treated with adjuvant chemotherapy and anti-HER2 therapy—a sub-analysis of the ALTTO study. British Journal of Cancer. 127(10). 1799–1807.
7.
Franzoi, Maria Alice, et al.. (2021). Clinical outcomes of platinum-based chemotherapy in patients with advanced breast cancer: An 11-year single institutional experience. The Breast. 57. 86–94.
8.
Dang, Chau T., Michael S. Ewer, Suzette Delaloge, et al.. (2021). 43O Pertuzumab/trastuzumab in early stage HER2-positive breast cancer: 5-year and final analysis of the BERENICE trial. Annals of Oncology. 32. S38–S39.
9.
Azambuja, Evandro de, Daniel Eiger, Marion Procter, et al.. (2021). Cardiac safety of dual anti-HER2 blockade with pertuzumab plus trastuzumab (P+T) in the APHINITY trial.. Journal of Clinical Oncology. 39(15_suppl). 510–510.
10.
Huober, Jens, Carlos H. Barrios, Naoki Niikura, et al.. (2021). VP6-2021: IMpassion050: A phase III study of neoadjuvant atezolizumab + pertuzumab + trastuzumab + chemotherapy (neoadj A + PH + CT) in high-risk, HER2-positive early breast cancer (EBC). Annals of Oncology. 32(8). 1061–1062.
11.
Eiger, Daniel, Noam Pondé, Dominique Agbor‐Tarh, et al.. (2020). Long-term cardiac outcomes of patients with HER2-positive breast cancer treated in the adjuvant lapatinib and/or trastuzumab Treatment Optimization Trial. British Journal of Cancer. 122(10). 1453–1460.
12.
Franzoi, Maria Alice, Caroline Vandeputte, Daniel Eiger, et al.. (2020). Computed tomography-based analyses of baseline body composition parameters and changes in breast cancer patients under treatment with CDK 4/6 inhibitors. Breast Cancer Research and Treatment. 181(1). 199–209.
13.
Eiger, Daniel, Christian Maurer, Mariana Brandão, et al.. (2020). 348P First findings from SYNERGY, a phase I/II trial testing the addition of the anti-CD73 oleclumab (O) to the anti-PD-L1 durvalumab (D) and chemotherapy (ChT) as first line therapy for patients (pts) with metastatic triple-negative breast cancer (mTNBC). Annals of Oncology. 31. S386–S387.
14.
Eiger, Daniel, Maria Alice Franzoi, Noam Pondé, et al.. (2020). Cardiotoxicity of trastuzumab given for 12 months compared to shorter treatment periods: a systematic review and meta-analysis of six clinical trials. ESMO Open. 5(1). e000659–e000659.
15.
Eiger, Daniel, Noam Pondé, & Evandro de Azambuja. (2019). Pertuzumab In Her2-Positive Early Breast Cancer: Current Use And Perspectives. Future Oncology. 15(16). 1823–1843.
16.
Maurer, Christian, Daniel Eiger, Philippe Aftimos, et al.. (2019). SYNERGY: Phase I and randomized phase II trial to investigate the addition of the anti-CD73 antibody oleclumab to durvalumab, paclitaxel and carboplatin for previously untreated, locally recurrent inoperable or metastatic triple-negative breast cancer (TNBC). Annals of Oncology. 30. iii62–iii62.
17.
Eiger, Daniel, Noam Pondé, Dominique Agbor‐Tarh, et al.. (2019). Long-term cardiac outcomes of HER2+ breast cancer patients treated in the ALTTO trial. Annals of Oncology. 30. iii65–iii65.
18.
Brandão, Mariana, Rafael Caparica, Daniel Eiger, & Evandro de Azambuja. (2019). Biomarkers of response and resistance to PI3K inhibitors in estrogen receptor-positive breast cancer patients and combination therapies involving PI3K inhibitors. Annals of Oncology. 30(Suppl_10). x27–x42.
19.
Eiger, Daniel, et al.. (2018). Complete lymphadenectomy following positive sentinel lymph node biopsy in cutaneous melanoma: a critical review. Anais Brasileiros de Dermatologia. 93(4). 553–558.
20.
Taranto, Patrícia, et al.. (2018). Continuous palliative sedation for patients with advanced cancer at a tertiary care cancer center. BMC Palliative Care. 17(1). 13–13.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by James Hu Breakdown of academic impact, for papers by Birgitta I. Hiddinga Breakdown of academic impact, for papers by Georgios Tsakonas Breakdown of academic impact, for papers by J. Crawford Breakdown of academic impact, for papers by Hirak Der‐Torossian Breakdown of academic impact, for papers by İbrahim Petekkaya Breakdown of academic impact, for papers by Munveer S. Bhangoo Breakdown of academic impact, for papers by Hiroshi Hongo Breakdown of academic impact, for papers by Eirini Papadopoulou Breakdown of academic impact, for papers by Alexandre de Nonneville